Genetically  ||| S:0 E:12 ||| RB
modified  ||| S:12 E:21 ||| VBN
cellular  ||| S:21 E:30 ||| JJ
vaccines  ||| S:30 E:39 ||| NNS
against  ||| S:39 E:47 ||| IN
human  ||| S:47 E:53 ||| JJ
papillomavirus  ||| S:53 E:68 ||| JJ
type  ||| S:68 E:73 ||| NN
16  ||| S:73 E:76 ||| CD
( ||| S:76 E:77 ||| -LRB-
HPV16 ||| S:77 E:82 ||| NNP
) ||| S:82 E:83 ||| -RRB-
-associated  ||| S:83 E:95 ||| JJ
tumors ||| S:95 E:101 ||| NNS
:  ||| S:101 E:103 ||| :
adjuvant  ||| S:103 E:112 ||| JJ
treatment  ||| S:112 E:122 ||| NN
of  ||| S:122 E:125 ||| IN
minimal  ||| S:125 E:133 ||| JJ
residual  ||| S:133 E:142 ||| JJ
disease  ||| S:142 E:150 ||| NN
after  ||| S:150 E:156 ||| IN
surgery ||| S:156 E:163 ||| NN
/ ||| S:163 E:164 ||| CD
chemotherapy  ||| S:164 E:177 ||| CD
Local  ||| S:177 E:183 ||| JJ
recurrences  ||| S:183 E:195 ||| NN
at  ||| S:195 E:198 ||| IN
the  ||| S:198 E:202 ||| DT
site  ||| S:202 E:207 ||| NN
of  ||| S:207 E:210 ||| IN
tumor  ||| S:210 E:216 ||| NN
resection  ||| S:216 E:226 ||| NNS
or  ||| S:226 E:229 ||| CC
after  ||| S:229 E:235 ||| IN
chemotherapy ||| S:235 E:247 ||| NN
,  ||| S:247 E:249 ||| ,
as  ||| S:249 E:252 ||| RB
well  ||| S:252 E:257 ||| RB
as  ||| S:257 E:260 ||| IN
distant  ||| S:260 E:268 ||| JJ
micrometastases  ||| S:268 E:284 ||| NNS
represent  ||| S:284 E:294 ||| VBP
major  ||| S:294 E:300 ||| JJ
problems  ||| S:300 E:309 ||| NNS
in  ||| S:309 E:312 ||| IN
oncology ||| S:312 E:320 ||| NN
.  ||| S:320 E:322 ||| .
Therapeutic  ||| S:322 E:334 ||| JJ
strategies  ||| S:334 E:345 ||| NNS
based  ||| S:345 E:351 ||| VBN
on  ||| S:351 E:354 ||| IN
insertion  ||| S:354 E:364 ||| NN
of  ||| S:364 E:367 ||| IN
immunostimulatory  ||| S:367 E:385 ||| JJ
genes  ||| S:385 E:391 ||| NNS
into  ||| S:391 E:396 ||| IN
the  ||| S:396 E:400 ||| DT
genome  ||| S:400 E:407 ||| NN
of  ||| S:407 E:410 ||| IN
tumor  ||| S:410 E:416 ||| NN
cells  ||| S:416 E:422 ||| NNS
followed  ||| S:422 E:431 ||| VBN
by  ||| S:431 E:434 ||| IN
vaccination  ||| S:434 E:446 ||| NN
with  ||| S:446 E:451 ||| IN
the  ||| S:451 E:455 ||| DT
resulting  ||| S:455 E:465 ||| VBG
genetically  ||| S:465 E:477 ||| RB
modified  ||| S:477 E:486 ||| VBN
and  ||| S:486 E:490 ||| CC
irradiated  ||| S:490 E:501 ||| JJ
cellular  ||| S:501 E:510 ||| JJ
vaccines  ||| S:510 E:519 ||| NNS
represent  ||| S:519 E:529 ||| VBP
a  ||| S:529 E:531 ||| DT
new  ||| S:531 E:535 ||| JJ
potential  ||| S:535 E:545 ||| JJ
prospect  ||| S:545 E:554 ||| NN
for  ||| S:554 E:558 ||| IN
the  ||| S:558 E:562 ||| DT
treatment  ||| S:562 E:572 ||| NN
of  ||| S:572 E:575 ||| IN
cancer  ||| S:575 E:582 ||| NN
patients ||| S:582 E:590 ||| NNS
.  ||| S:590 E:592 ||| .
These  ||| S:592 E:598 ||| DT
strategies  ||| S:598 E:609 ||| NNS
are  ||| S:609 E:613 ||| VBP
based  ||| S:613 E:619 ||| VBN
on  ||| S:619 E:622 ||| IN
the  ||| S:622 E:626 ||| DT
presumption  ||| S:626 E:638 ||| NN
that  ||| S:638 E:643 ||| IN
many ||| S:643 E:647 ||| JJ
,  ||| S:647 E:649 ||| ,
if  ||| S:649 E:652 ||| IN
not  ||| S:652 E:656 ||| RB
all  ||| S:656 E:660 ||| DT
tumors ||| S:660 E:666 ||| NNS
,  ||| S:666 E:668 ||| ,
possess  ||| S:668 E:676 ||| JJ
cell  ||| S:676 E:681 ||| NN
surface  ||| S:681 E:689 ||| NN
antigens  ||| S:689 E:698 ||| VBZ
capable  ||| S:698 E:706 ||| JJ
of  ||| S:706 E:709 ||| IN
being  ||| S:709 E:715 ||| VBG
recognized  ||| S:715 E:726 ||| VBN
by  ||| S:726 E:729 ||| IN
defence  ||| S:729 E:737 ||| JJ
effectors  ||| S:737 E:747 ||| NN
of  ||| S:747 E:750 ||| IN
the  ||| S:750 E:754 ||| DT
immune  ||| S:754 E:761 ||| JJ
system ||| S:761 E:767 ||| NN
,  ||| S:767 E:769 ||| ,
as  ||| S:769 E:772 ||| RB
well  ||| S:772 E:777 ||| RB
as  ||| S:777 E:780 ||| RB
on  ||| S:780 E:783 ||| IN
the  ||| S:783 E:787 ||| DT
presumption  ||| S:787 E:799 ||| NN
that  ||| S:799 E:804 ||| IN
local  ||| S:804 E:810 ||| JJ
treatment  ||| S:810 E:820 ||| NN
of  ||| S:820 E:823 ||| IN
primary  ||| S:823 E:831 ||| JJ
tumors  ||| S:831 E:838 ||| NNS
can ||| S:838 E:841 ||| MD
,  ||| S:841 E:843 ||| ,
due  ||| S:843 E:847 ||| JJ
to  ||| S:847 E:850 ||| TO
its  ||| S:850 E:854 ||| PRP$
immunizing  ||| S:854 E:865 ||| JJ
potential ||| S:865 E:874 ||| NN
,  ||| S:874 E:876 ||| ,
result  ||| S:876 E:883 ||| NN
also  ||| S:883 E:888 ||| RB
in  ||| S:888 E:891 ||| IN
the  ||| S:891 E:895 ||| DT
inhibition  ||| S:895 E:906 ||| NN
of  ||| S:906 E:909 ||| IN
distant  ||| S:909 E:917 ||| JJ
metastases ||| S:917 E:927 ||| NN
.  ||| S:927 E:929 ||| .
Genetically  ||| S:929 E:941 ||| RB
modified  ||| S:941 E:950 ||| VBN
cellular  ||| S:950 E:959 ||| JJ
vaccines  ||| S:959 E:968 ||| NNS
were  ||| S:968 E:973 ||| VBD
found  ||| S:973 E:979 ||| VBN
to  ||| S:979 E:982 ||| TO
be  ||| S:982 E:985 ||| VB
efficient  ||| S:985 E:995 ||| JJ
against  ||| S:995 E:1003 ||| IN
cancer  ||| S:1003 E:1010 ||| NN
both  ||| S:1010 E:1015 ||| CC
in  ||| S:1015 E:1018 ||| IN
experimental  ||| S:1018 E:1031 ||| JJ
models  ||| S:1031 E:1038 ||| NNS
and  ||| S:1038 E:1042 ||| CC
in  ||| S:1042 E:1045 ||| IN
tumor-bearing  ||| S:1045 E:1059 ||| JJ
patients ||| S:1059 E:1067 ||| NNS
.  ||| S:1067 E:1069 ||| .
It  ||| S:1069 E:1072 ||| PRP
was  ||| S:1072 E:1076 ||| VBD
also  ||| S:1076 E:1081 ||| RB
shown  ||| S:1081 E:1087 ||| VBN
in  ||| S:1087 E:1090 ||| IN
various  ||| S:1090 E:1098 ||| JJ
systems  ||| S:1098 E:1106 ||| NNS
that  ||| S:1106 E:1111 ||| IN
the  ||| S:1111 E:1115 ||| DT
efficacy  ||| S:1115 E:1124 ||| NN
of  ||| S:1124 E:1127 ||| IN
conventional  ||| S:1127 E:1140 ||| JJ
therapeutic  ||| S:1140 E:1152 ||| JJ
modalities  ||| S:1152 E:1163 ||| NN
can  ||| S:1163 E:1167 ||| MD
be  ||| S:1167 E:1170 ||| VB
supported  ||| S:1170 E:1180 ||| VBN
by  ||| S:1180 E:1183 ||| IN
adjuvant  ||| S:1183 E:1192 ||| JJ
administration  ||| S:1192 E:1207 ||| NN
of  ||| S:1207 E:1210 ||| IN
genetically  ||| S:1210 E:1222 ||| RB
modified  ||| S:1222 E:1231 ||| VBN
vaccines ||| S:1231 E:1239 ||| NNS
,  ||| S:1239 E:1241 ||| ,
as  ||| S:1241 E:1244 ||| RB
well  ||| S:1244 E:1249 ||| RB
as  ||| S:1249 E:1252 ||| RB
by  ||| S:1252 E:1255 ||| IN
depletion  ||| S:1255 E:1265 ||| NN
of  ||| S:1265 E:1268 ||| IN
immunosuppressive  ||| S:1268 E:1286 ||| JJ
immunocyte  ||| S:1286 E:1297 ||| JJ
subsets ||| S:1297 E:1304 ||| NN
.  ||| S:1304 E:1306 ||| .
The  ||| S:1306 E:1310 ||| DT
purpose  ||| S:1310 E:1318 ||| NN
of  ||| S:1318 E:1321 ||| IN
this  ||| S:1321 E:1326 ||| DT
review  ||| S:1326 E:1333 ||| NN
was  ||| S:1333 E:1337 ||| VBD
to  ||| S:1337 E:1340 ||| TO
summarize  ||| S:1340 E:1350 ||| VB
and  ||| S:1350 E:1354 ||| CC
evaluate  ||| S:1354 E:1363 ||| VB
the  ||| S:1363 E:1367 ||| DT
results  ||| S:1367 E:1375 ||| NNS
obtained  ||| S:1375 E:1384 ||| VBN
with  ||| S:1384 E:1389 ||| IN
the  ||| S:1389 E:1393 ||| DT
administration  ||| S:1393 E:1408 ||| NN
of  ||| S:1408 E:1411 ||| IN
genetically  ||| S:1411 E:1423 ||| RB
modified  ||| S:1423 E:1432 ||| VBN
cellular  ||| S:1432 E:1441 ||| JJ
vaccines  ||| S:1441 E:1450 ||| NNS
as  ||| S:1450 E:1453 ||| IN
well  ||| S:1453 E:1458 ||| RB
as  ||| S:1458 E:1461 ||| RB
with  ||| S:1461 E:1466 ||| IN
depletion  ||| S:1466 E:1476 ||| NN
of  ||| S:1476 E:1479 ||| IN
immunosuppressive  ||| S:1479 E:1497 ||| NNS
immunocytes  ||| S:1497 E:1509 ||| VBP
performed  ||| S:1509 E:1519 ||| VBN
as  ||| S:1519 E:1522 ||| IN
treatment  ||| S:1522 E:1532 ||| NN
of  ||| S:1532 E:1535 ||| IN
minimal  ||| S:1535 E:1543 ||| JJ
residual  ||| S:1543 E:1552 ||| JJ
disease  ||| S:1552 E:1560 ||| NN
after  ||| S:1560 E:1566 ||| IN
surgery  ||| S:1566 E:1574 ||| NN
/  ||| S:1574 E:1576 ||| CD
chemotherapy  ||| S:1576 E:1589 ||| NN
in  ||| S:1589 E:1592 ||| IN
the  ||| S:1592 E:1596 ||| DT
experimental  ||| S:1596 E:1609 ||| JJ
model  ||| S:1609 E:1615 ||| NN
of  ||| S:1615 E:1618 ||| IN
murine  ||| S:1618 E:1625 ||| FW
tumors  ||| S:1625 E:1632 ||| FW
mimicking  ||| S:1632 E:1642 ||| FW
human  ||| S:1642 E:1648 ||| FW
HPV16-associated  ||| S:1648 E:1665 ||| FW
neoplasms ||| S:1665 E:1674 ||| FW
.  ||| S:1674 E:1676 ||| .
The  ||| S:1676 E:1680 ||| DT
prospects  ||| S:1680 E:1690 ||| NNS
and  ||| S:1690 E:1694 ||| CC
limitations  ||| S:1694 E:1706 ||| NNS
of  ||| S:1706 E:1709 ||| IN
these  ||| S:1709 E:1715 ||| DT
adjuvant  ||| S:1715 E:1724 ||| JJ
immunotherapeutic  ||| S:1724 E:1742 ||| JJ
modalities  ||| S:1742 E:1753 ||| NNS
are  ||| S:1753 E:1757 ||| VBP
discussed ||| S:1757 E:1766 ||| VBN
.  ||| S:1766 E:1768 ||| .
